Latest news
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma - The American Journal of Managed CareThe American Journal of Managed Care · Wed, 05 Aug 2026 15:30:00 GMTFDA Approval Insights: Subcutaneous Isatuximab Via an On-Body Delivery System Represents a “Game-Changer” in Multiple Myeloma: With Douglas W. Sborov, MD, MS - OncLiveOncLive · Sat, 01 Aug 2026 03:04:52 GMTHow Subcutaneous Isatuximab Could Compete With Daratumumab in Multiple Myeloma - Pharmacy TimesPharmacy Times · Tue, 28 Jul 2026 20:03:31 GMTMultiple Myeloma Isatuximabirfc Expanded Indications - Specialty Pharmacy ContinuumSpecialty Pharmacy Continuum · Tue, 28 Jul 2026 01:09:38 GMT